ENZ
Enzo Biochem, Inc.
Set alert
52-week range unavailable
- YTD
- -56.07%
- 1 year
- -72.71%
- Open
- 0.3702
- Prev close
- 0.3138
- Mkt cap
- 38.71M
- Vol
- 4.12M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 39.60%
More statistics
- Low
- 0.3138
- High
- 0.40
- Forward P/E
- -1.90
- Beta
- 0.73
- Short ratio
- 2.80
- Inst. own
- 31.79%
- Dividend
- 0.40
- Ex-div date
- Nov 14, 2024
- Earnings
- Nov 4, 2024
- 50-d avg
- 1.06
- 200-d avg
- 1.12
- 1y target
- 0.00
Key statistics
- Market cap
- 38.71M
- Enterprise value
- 3.90M
- Trailing P/E
- 0.00
- Forward P/E
- -1.90
- PEG ratio
- 0.00
- Price / sales
- 1.21
- Price / book
- 0.69
- EPS (TTM)
- -0.15
- Beta
- 0.73
- Dividend yield
- 39.60%
- Payout ratio
- 0.00%
- Profit margin
- -81.73%
- Revenue (TTM)
- 31.91M
- Revenue growth
- 0.00%
- Free cash flow
- -18.95M
- Total cash
- 52.37M
- Total debt
- 3.51M
- Return on equity
- -14.59%
- Shares outstanding
- 52.24M
- Short % of float
- 0.90%
- 50-day average
- 1.06
- 200-day average
- 1.12
Analyst view
Consensus: none
Next earnings
Nov 4, 2024
Expected Nov 4, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 16, 2024 | Oct 1, 2024 | 0.00 | -0.05 | — | — |
| Nov 4, 2024 | Jul 1, 2024 | 0.00 | — | — | — |
| Jun 13, 2024 | Apr 1, 2024 | 0.00 | -0.03 | — | — |
| Mar 13, 2024 | Jan 1, 2024 | 0.00 | 0.00 | — | — |
| Dec 15, 2023 | Oct 1, 2023 | 0.00 | -0.11 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 4, 2014 | Craig-Hallum | init | — | Buy |
| Jul 2, 2013 | Sidoti & Co. | init | — | Neutral |
About Enzo Biochem, Inc.
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- enzo.com
News
- Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction
- Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
- Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction
- The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment
- Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
Your note
Sign in to keep a note on ENZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANNON KARA | Chief Executive Officer | Stock Award(Grant) | Feb 22, 2024 | 496,362 |
| PULLY STEVEN J | Director | Stock Award(Grant) | Jan 30, 2024 | 97,095 |
| RADOFF BRADLEY LOUIS | Director | Stock Award(Grant) | Jan 30, 2024 | 4,820,880 |
| TAGLIAFERRI MARY ANN | Director | Stock Award(Grant) | Jan 30, 2024 | 312,383 |
| WALTERS IAN B. | Director | Stock Award(Grant) | Feb 12, 2023 | 155,917 |
| WOLF JAMES G | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 12, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Harbert Fund Advisors, Inc. | 9.91% | 5,175,913 | 3.84M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 4.84% | 2,527,529 | 1.87M | Sep 29, 2024 |
| Vanguard Group Inc | 3.59% | 1,876,622 | 1.39M | Sep 29, 2024 |
| Blackrock Inc. | 1.84% | 959,151 | 710.73K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.71% | 368,646 | 273.17K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 0.58% | 304,492 | 225.63K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.27% | 1,187,908 | 880.24K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 618,881 | 458.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.41% | 216,370 | 160.33K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.34% | 175,200 | 129.82K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.19% | 99,803 | 73.95K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.16% | 82,649 | 61.24K | Jul 30, 2024 |